Published in Br J Clin Pharmacol on January 01, 2014
Eligibility requirements for community pharmacy medication review services in Canada. Can Pharm J (Ott) (2014) 1.69
New models of chronic kidney disease care including pharmacists: improving medication reconciliation and medication management. Curr Opin Nephrol Hypertens (2013) 0.84
The impact of a medication review with follow-up service on hospital admissions in aged polypharmacy patients. Br J Clin Pharmacol (2016) 0.82
Do pharmacist-led medication reviews in hospitals help reduce hospital readmissions? A systematic review and meta-analysis. Br J Clin Pharmacol (2016) 0.80
Medication Regimen Complexity and Number of Medications as Factors Associated With Unplanned Hospitalizations in Older People: A Population-based Cohort Study. J Gerontol A Biol Sci Med Sci (2015) 0.79
Effectiveness of the clinical pharmacist in reducing mortality in hospitalized cardiac patients: a propensity score-matched analysis. Ther Clin Risk Manag (2016) 0.78
Uptake of the MedsCheck annual medication review service in Ontario community pharmacies between 2007 and 2013. Can Pharm J (Ott) (2016) 0.78
Impact of a community pharmacist-led medication review on medicines use in patients on polypharmacy - a prospective randomised controlled trial. BMC Health Serv Res (2016) 0.76
Patient opinions on medicine-use review: exploring an expanding role of community pharmacists. Patient Prefer Adherence (2017) 0.75
An integrated general practice and pharmacy-based intervention to promote the use of appropriate preventive medications among individuals at high cardiovascular disease risk: protocol for a cluster randomized controlled trial. Implement Sci (2016) 0.75
Patients' perception of pharmaceutical services available in a community pharmacy among patients living in a rural area of the United Kingdom. Pharm Pract (Granada) (2016) 0.75
Improving medication safety: Development and impact of a multivariate model-based strategy to target high-risk patients. PLoS One (2017) 0.75
Effectiveness of medication review: a systematic review and meta-analysis of randomized controlled trials. BMC Fam Pract (2017) 0.75
Impact of a pharmacist-led medication review on hospital readmission in a pediatric and elderly population: study protocol for a randomized open-label controlled trial. Trials (2017) 0.75
Medicines Management, Medication Errors and Adverse Medication Events in Older People Referred to a Community Nursing Service: A Retrospective Observational Study. Drugs Real World Outcomes (2016) 0.75
A cluster randomised control trial to evaluate the effectiveness and cost-effectiveness of the Italian medicines use review (I-MUR) for asthma patients. BMC Health Serv Res (2017) 0.75
Education and Assessment of Pharmacists on the Use of the Drug Burden Index in Older Adults Using a Continuing Professional Development Education Method. Am J Pharm Educ (2016) 0.75
Development of a core outcome set for medication review in older patients with multimorbidity and polypharmacy: a study protocol. Clin Interv Aging (2017) 0.75
Prevalence and implications of cytochrome P450 substrates in Massachusetts hospital discharges. Pharmacogenomics J (2016) 0.75
Challenges in the management of community pharmacies in Malaysia. Pharm Pract (Granada) (2017) 0.75
US pharmacists' effect as team members on patient care: systematic review and meta-analyses. Med Care (2010) 4.65
Medication therapy management in pharmacy practice: core elements of an MTM service model (version 2.0). J Am Pharm Assoc (2003) (2008) 4.41
Pharmacist care of patients with heart failure: a systematic review of randomized trials. Arch Intern Med (2008) 2.55
Does pharmacist-led medication review help to reduce hospital admissions and deaths in older people? A systematic review and meta-analysis. Br J Clin Pharmacol (2007) 2.44
Pharmacist intervention program for control of hypertension. Ann Pharmacother (2003) 2.14
Effectiveness of pharmacist intervention for asthma control improvement. Eur Respir J (2007) 2.13
A randomized controlled trial of a pharmacist consultation program for family physicians and their elderly patients. CMAJ (2003) 1.93
Clinical and economic outcomes of medication therapy management services: the Minnesota experience. J Am Pharm Assoc (2003) (2008) 1.93
Sensitivity of patient outcomes to pharmacist interventions. Part II: Systematic review and meta-analysis in hypertension management. Ann Pharmacother (2007) 1.90
Pharmacy Asthma Care Program (PACP) improves outcomes for patients in the community. Thorax (2007) 1.84
Impact of a collaborative pharmacy practice model on the treatment of depression in primary care. Am J Health Syst Pharm (2002) 1.82
Improving drug therapy for patients with asthma--part 1: Patient outcomes. J Am Pharm Assoc (Wash) (2001) 1.82
Evaluation of hypertensive patients after care provided by community pharmacists in a rural setting. Pharmacotherapy (1998) 1.54
Improving drug therapy for patients with asthma-part 2: Use of antiasthma medications. J Am Pharm Assoc (Wash) (2001) 1.52
Providing diabetes education and care to underserved patients in a collaborative practice at a utah community health center. Pharmacotherapy (2005) 1.51
Effect of a pharmacist-led intervention on diuretic compliance in heart failure patients: a randomized controlled study. J Card Fail (2003) 1.50
Pharmaceutical care and health care utilization in an HMO. Eff Clin Pract (2002) 1.48
A systematic review of the evidence for pharmacist care of patients with dyslipidemia. Pharmacotherapy (2012) 1.42
The MEDMAN study: a randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease. Fam Pract (2007) 1.41
Effectiveness of visits from community pharmacists for patients with heart failure: HeartMed randomised controlled trial. BMJ (2007) 1.38
Assessment of a community pharmacy-based program for patients with asthma. Pharmacotherapy (2001) 1.36
Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medi-Cal beneficiaries. J Manag Care Pharm (2009) 1.35
Evaluation of a hypertension medication therapy management program in patients with diabetes. J Am Pharm Assoc (2003) (2009) 1.26
Evaluation of the Iowa Medicaid pharmaceutical case management program. J Am Pharm Assoc (2003) (2004) 1.22
Comprehensive pharmaceutical care in the chain setting. J Am Pharm Assoc (Wash) (1996) 1.22
Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiol Drug Saf (2006) 1.14
Impact on medication use and adherence of Australian pharmacists' diabetes care services. J Am Pharm Assoc (2003) (2005) 1.13
Impact of a pharmaceutical care program in a community pharmacy on patients with dyslipidemia. Ann Pharmacother (2005) 1.09
A cluster randomized controlled Trial to Evaluate an Ambulatory primary care Management program for patients with dyslipidemia: the TEAM study. CMAJ (2010) 1.09
Pharmaceutical care services for asthma patients: a controlled intervention study. J Clin Pharmacol (2001) 1.09
Economic evaluation of pharmacist involvement in disease management in a community pharmacy setting. Clin Ther (1997) 1.09
Improving primary care in rural Alabama with a pharmacy initiative. Am J Health Syst Pharm (2003) 1.08
Community pharmacy based provision of pharmaceutical care to older patients. Pharm World Sci (2003) 1.07
Home-based medication review in a high risk elderly population in primary care--the POLYMED randomised controlled trial. Age Ageing (2007) 1.07
Medication review and patient counselling at discharge from the hospital by community pharmacists. Pharm World Sci (2009) 1.01
The effectiveness of collaborative medicine reviews in delaying time to next hospitalization for patients with heart failure in the practice setting: results of a cohort study. Circ Heart Fail (2009) 1.00
Examining the first year of Medicines Use Review services provided by pharmacists in New Zealand: 2008. N Z Med J (2009) 0.99
An evaluation of a community pharmacy-based rural asthma management service. Aust J Rural Health (2008) 0.93
A self-reported work-sampling study in community pharmacy practice: a 2009 update. Pharm World Sci (2010) 0.86
A learning-based approach for performing an in-depth literature search using MEDLINE. J Clin Pharm Ther (2010) 0.86
Pharmaceutical care for patients with ischemic stroke: improving the patients quality of life. Pharm World Sci (2009) 0.82
Costs of a community pharmacist-led medicines management service for patients with coronary heart disease in England: healthcare system and patient perspectives. Pharmacoeconomics (2007) 0.82
Evaluation of a pilot medication therapy management project within the North Carolina State Health Plan. J Am Pharm Assoc (2003) (2007) 0.82
Quantification of lean bodyweight. Clin Pharmacokinet (2005) 3.59
Impaired nitric oxide bioavailability and L-arginine reversible endothelial dysfunction in adults with falciparum malaria. J Exp Med (2007) 3.13
Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. Proc Natl Acad Sci U S A (2008) 2.80
Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose. Intensive Care Med (2006) 2.65
A 3-dimensional view of access to licensed and subsidized medicines under single-payer systems in the US, the UK, Australia and New Zealand. Pharmacoeconomics (2012) 2.14
What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol (2004) 2.01
Relationship of cell-free hemoglobin to impaired endothelial nitric oxide bioavailability and perfusion in severe falciparum malaria. J Infect Dis (2009) 1.86
A dosing regimen for immediate N-acetylcysteine treatment for acute paracetamol overdose. Clin Toxicol (Phila) (2011) 1.66
Methanol and ethylene glycol acute poisonings - predictors of mortality. Clin Toxicol (Phila) (2011) 1.59
Activated charcoal decreases the risk of QT prolongation after citalopram overdose. Ann Emerg Med (2007) 1.58
Routine plasma anti-Xa monitoring is required for low-molecular-weight heparins. Clin Pharmacokinet (2010) 1.41
Continuation of proton pump inhibitors from hospital to community. Pharm World Sci (2006) 1.39
Disposal practices for unused medications around the world. Environ Int (2011) 1.38
A reduction in between subject variability is not mandatory for selecting a new covariate. J Pharmacokinet Pharmacodyn (2012) 1.38
Increased asymmetric dimethylarginine in severe falciparum malaria: association with impaired nitric oxide bioavailability and fatal outcome. PLoS Pathog (2010) 1.37
A generalisation of T-optimality for discriminating between competing models with an application to pharmacokinetic studies. Pharm Stat (2012) 1.30
Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses. Br J Clin Pharmacol (2006) 1.30
The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approach. J Pharmacokinet Pharmacodyn (2005) 1.28
Recovery of endothelial function in severe falciparum malaria: relationship with improvement in plasma L-arginine and blood lactate concentrations. J Infect Dis (2008) 1.26
Studying drugs in human milk: time to unify the approach. J Hum Lact (2002) 1.22
Pediatric licensing status and the availability of suitable formulations for new medical entities approved in the United States between 1998 and 2002. J Clin Pharmacol (2006) 1.19
Effect of the pediatric exclusivity provision on children's access to medicines. Br J Clin Pharmacol (2005) 1.19
Development of a dosing strategy for enoxaparin in obese patients. Br J Clin Pharmacol (2003) 1.13
Prospective evaluation of a D-optimal designed population pharmacokinetic study. J Pharmacokinet Pharmacodyn (2003) 1.13
Analysis of medications returned to community pharmacies. Ann Pharmacother (2009) 1.12
Trends in accessibility to medicines for children in New Zealand: 1998-2002. Br J Clin Pharmacol (2004) 1.11
Changes in availability of paediatric medicines in Australia between 1998 and 2002. Br J Clin Pharmacol (2005) 1.10
Is the dose of dabigatran really more predictable than warfarin? Br J Clin Pharmacol (2013) 1.07
Red blood cell survival in long-term dialysis patients. Am J Kidney Dis (2011) 1.06
Lean body mass normalizes the effect of obesity on renal function. Br J Clin Pharmacol (2008) 1.05
Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria. Malar J (2011) 1.02
A randomized pilot study of L-arginine infusion in severe falciparum malaria: preliminary safety, efficacy and pharmacokinetics. PLoS One (2013) 1.02
A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. J Pain (2009) 1.02
Examining the first year of Medicines Use Review services provided by pharmacists in New Zealand: 2008. N Z Med J (2009) 0.99
Optimal designs for population pharmacokinetic studies of the partner drugs co-administered with artemisinin derivatives in patients with uncomplicated falciparum malaria. Malar J (2012) 0.99
Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients. J Pharmacokinet Pharmacodyn (2005) 0.98
Amisulpride overdose is frequently associated with QT prolongation and torsades de pointes. J Clin Psychopharmacol (2010) 0.97
A Bayesian approach for population pharmacokinetic modelling of sirolimus. Br J Clin Pharmacol (2006) 0.96
Assessment of markers of glycaemic control in diabetic patients with chronic kidney disease using continuous glucose monitoring. Nephrology (Carlton) (2012) 0.96
A population pharmacokinetic model for low-dose methotrexate and its polyglutamated metabolites in red blood cells. Clin Pharmacokinet (2013) 0.95
Quetiapine overdose: predicting intubation, duration of ventilation, cardiac monitoring and the effect of activated charcoal. Int Clin Psychopharmacol (2009) 0.93
Is the ideal anticoagulant a myth? Expert Rev Clin Pharmacol (2012) 0.92
Establishing a baseline for the monitoring of medicines availability for children in the UK: 1998-2002. Br J Clin Pharmacol (2006) 0.92
Pharmacokinetics of L-arginine in adults with moderately severe malaria. Antimicrob Agents Chemother (2008) 0.92
Safety profile of L-arginine infusion in moderately severe falciparum malaria. PLoS One (2008) 0.92
Development of a sufficient design for estimation of fluconazole pharmacokinetics in people with HIV infection. Br J Clin Pharmacol (2008) 0.91
Understanding the time course of pharmacological effect: a PKPD approach. Br J Clin Pharmacol (2011) 0.91
Access to prescribing information for paediatric medicines in the USA: post-modernization. Br J Clin Pharmacol (2008) 0.91
Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation. Eur J Clin Pharmacol (2005) 0.91
The time course of drug effects. Pharm Stat (2009) 0.90
The population pharmacokinetics of allopurinol and oxypurinol in patients with gout. Eur J Clin Pharmacol (2013) 0.90
Estimation of pharmacokinetic parameters from non-compartmental variables using Microsoft Excel. Comput Biol Med (2005) 0.90
General practitioners' perceptions of pharmacists' new services in New Zealand. Int J Clin Pharm (2012) 0.90
A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. Br J Clin Pharmacol (2006) 0.90
Impact of anticholinergic discontinuation on cognitive outcomes in older people: a systematic review. Drugs Aging (2014) 0.89
Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation. Br J Clin Pharmacol (2006) 0.88
Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia. Ther Drug Monit (2004) 0.88
Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. Br J Clin Pharmacol (2010) 0.87
A robust design for identification of the Parasite Clearance Estimator. Malar J (2013) 0.87
A Bayesian dose-individualization method for warfarin. Clin Pharmacokinet (2013) 0.86
Modeling red blood cell survival data. J Pharmacokinet Pharmacodyn (2011) 0.86
GFR may not accurately predict aspects of proximal tubule drug handling. Eur J Clin Pharmacol (2014) 0.86
Disposal practices for unused medications in New Zealand community pharmacies. J Prim Health Care (2011) 0.85
The impact of pharmaceutical cost containment policies on the range of medicines available and subsidized in Finland and New Zealand. Value Health (2009) 0.85
Towards optimal design of anti-malarial pharmacokinetic studies. Malar J (2009) 0.85
Effect of Australian elapid venoms on blood coagulation: Australian Snakebite Project (ASP-17). Toxicon (2012) 0.84
The use of a change in gentamicin clearance as an early predictor of gentamicin-induced nephrotoxicity. Ther Drug Monit (2003) 0.83
Methods to account for inaccuracies in the dosing history when performing population pharmacokinetic analysis. Pharm Res (2008) 0.83
Evaluation of red blood cell labelling methods based on a statistical model for red blood cell survival. J Theor Biol (2011) 0.83
The influence of dosing time, variable compliance and circadian low-density lipoprotein production on the effect of simvastatin: simulations from a pharmacokinetic-pharmacodynamic model. Basic Clin Pharmacol Toxicol (2011) 0.82
Documenting pharmacist's clinical interventions in New Zealand hospitals. Pharm World Sci (2007) 0.82
General practitioners' views of pharmacists' current and potential contributions to medication review and prescribing in New Zealand. J Prim Health Care (2013) 0.81
Sampling times for monitoring tacrolimus in stable adult liver transplant recipients. Ther Drug Monit (2004) 0.81
Modelling the occurrence and severity of enoxaparin-induced bleeding and bruising events. Br J Clin Pharmacol (2009) 0.81
Development of a bayesian forecasting method for warfarin dose individualization. Pharm Res (2011) 0.81
Pharmacists' performance of clinical interventions during adherence support medication reviews. Res Social Adm Pharm (2013) 0.81
Development and evaluation of a prototype of a novel clotting time test to monitor enoxaparin. Pharm Res (2011) 0.80
Assessment of the relationship between methotrexate polyglutamates in red blood cells and clinical response in patients commencing methotrexate for rheumatoid arthritis. Clin Pharmacokinet (2014) 0.80
The pharmacokinetics of sertraline in overdose and the effect of activated charcoal. Br J Clin Pharmacol (2015) 0.79
The effect of decontamination procedures on the pharmacodynamics of venlafaxine in overdose. Br J Clin Pharmacol (2011) 0.79
Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers. Diagn Microbiol Infect Dis (2009) 0.79
Design of pharmacokinetic studies for latent covariates. J Pharmacokinet Pharmacodyn (2011) 0.79
Between-subject variability: should high be the new normal? Eur J Clin Pharmacol (2014) 0.78
Evaluation of graphical diagnostics for assessing goodness of fit of logistic regression models. J Pharmacokinet Pharmacodyn (2010) 0.78
Parameterisation affects identifiability of population models. J Pharmacokinet Pharmacodyn (2013) 0.77
Retrospective examination of selected outcomes of Medicines Use Review (MUR) services in New Zealand. Int J Clin Pharm (2014) 0.77
Aminoglycoside dosage regimens after therapeutic drug monitoring. Clin Pharmacokinet (2002) 0.77
Key informants' perceptions of how pharmac operates in New Zealand. Int J Technol Assess Health Care (2012) 0.77
A semi-mechanistic red blood cell survival model provides some insight into red blood cell destruction mechanisms. J Pharmacokinet Pharmacodyn (2013) 0.77
A statistical model for red blood cell survival. J Theor Biol (2010) 0.77
Comparison of intracellular methotrexate kinetics in red blood cells with the kinetics in other cell types. Br J Clin Pharmacol (2014) 0.76
Health professionals: how do they assess new medicines? Pharm World Sci (2005) 0.76